Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Current Deferred Revenue (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Current Deferred Revenue data on record, last reported at $3.3 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 54.89% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $3.3 million, down 54.89%, while the annual FY2025 figure was $3.3 million, 54.89% down from the prior year.
  • Current Deferred Revenue reached $3.3 million in Q4 2025 per LCTX's latest filing, down from $3.8 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $45.6 million in Q1 2022 and bottomed at $101000.0 in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $12.0 million, with a median of $9.1 million recorded in 2024.
  • Peak YoY movement for Current Deferred Revenue: soared 45048.51% in 2022, then crashed 75.86% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $975000.0 in 2021, then skyrocketed by 866.26% to $9.4 million in 2022, then rose by 14.72% to $10.8 million in 2023, then tumbled by 31.64% to $7.4 million in 2024, then plummeted by 54.89% to $3.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $3.3 million in Q4 2025, $3.8 million in Q3 2025, and $5.3 million in Q2 2025.